Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.81 |
| ▸ | PRKAA1 | Q13131 | 15/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 13/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.81 |
| ▸ | EGFR | P00533 | 3/20 | 0.81 |
| ▸ | FLT3 | P36888 | 3/20 | 0.81 |
| ▸ | PLK4 | O00444 | 2/20 | 0.81 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.81 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.81 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.81 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.81 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.81 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.81 |
| ▸ | INSR | P06213 | 2/20 | 0.81 |
| ▸ | LCK | P06239 | 2/20 | 0.81 |
| ▸ | FYN | P06241 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726442 | 1.00 | KDR (0.81) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL15202704 | 0.91 | KDR (0.84) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL18651190 | 0.90 | KDR (0.85) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL18651294 | 0.90 | KDR (0.81) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Su-11652 SCHEMBL21067494 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343935 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL2116962 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL20805212 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| SCHEMBL5831195 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343938 | 0.90 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9808531-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808531-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | KDR 2062/4885PRKAA1 2821/4885PRKAA2 2644/4885 |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | KDR 724/4885PRKAA1 208/4885PRKAA2 242/4885 |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | KDR 205/4885PRKAA1 1042/4885PRKAA2 1436/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | KDR 205/4885PRKAA1 1042/4885PRKAA2 1436/4885 |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | PTGIR, PTGIS, CA2 | KDR 724/4885PRKAA1 208/4885PRKAA2 242/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | KDR 801/4885PRKAA1 1651/4885PRKAA2 1612/4885 |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | KDR 724/4885PRKAA1 208/4885PRKAA2 242/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | KDR 1573/4885PRKAA1 1470/4885PRKAA2 1617/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | KDR 205/4885PRKAA1 1042/4885PRKAA2 1436/4885 |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | AGER, PDE6B, PTGER1 | KDR 1368/4885PRKAA1 2571/4885PRKAA2 3149/4885 |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | KDR 724/4885PRKAA1 208/4885PRKAA2 242/4885 |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | KDR, RB1, PDE6C | KDR 1/4885PRKAA1 2383/4885PRKAA2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.